Finch Therapeutics is a biotech company that develops novel microbiome therapeutics. Its products include FIN-211, a microbiome designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorders as well as FIN-524, FIN-525, and other microbiome products for inflammatory bowel disease.